Skip to main content

Day: December 4, 2024

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream

Press ReleaseNicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream First commercialized product from the Nicox-Ocumension collaboration Recent acquisitions have enhanced OcuMension’s leadership in the ophthalmology field in the China market Product made available quickly after approval thanks to a rapid manufacturing campaign at Ocumension’s state-of-the-art factory Major milestone for this strong collaboration, which also includes our lead asset, NCX 470, where recruitment was just completed in the Denali Phase 3 trialDecember 4, 2024 – release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced the first commercial sale of ZERVIATE® (cetirizine ophthalmic...

Continue reading

KH Group: Indoor Group’s change negotiations have been concluded — the new operating model will be rolled out across the country

KH Group PlcPress release 4 December 2024 at 8:50 am EET KH Group: Indoor Group’s change negotiations have been concluded — the new operating model will be rolled out across the country   On 15 August 2024, KH Group announced an operating model reform programme aimed at improving the group company Indoor Group’s profitability. Change negotiations related to the reform began on 21 October 2024 and the scope of the negotiations covered 635 employees. At the start of the negotiations, the company estimated that the planned changes would lead to the termination of up to 200 positions. The outcome of the change negotiations is that 162 employment relationships will be terminated in Indoor Group. The change negotiations that have now been concluded are part of the company’s extensive operating model reform, which is focused on the nationwide...

Continue reading

Tryg launches a share buyback program of DKK 2bn

  The share buyback programme is launched with reference to the authorisation to acquire treasury shares granted by the general meeting on 21 March 2024. The authorisation is valid until 31 December 2025 and allows Tryg to acquire shares with a total nominal value of up to DKK 308,196,054 corresponding to app. 10% of its share capital. The share buyback programme will start on 04 December 2024 and end no later than 30 June 2025. The share buyback programme will be executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). Tryg has appointed Danske Bank A/S as lead manager of the share buyback programme. Under a separate agreement, Danske Bank A/S will within the announced limits...

Continue reading

Tryg hosts a Capital Markets Day and presents new targets for 2027

  Today, Tryg is hosting a Capital Markets Day in London to launch its new strategy “Leveraging scale to drive technical and commercial excellence” and setting new, ambitious, financial targets for 2027. Tryg expects to meet all the 2024 financial targets set at the previous Capital Markets Day in 2021. New financial targets and launch of DKK 2bn share buyback programTryg has set new financial targets for 2027. The company targets an insurance service result between DKK 8.0bn – 8.4 bn in 2027 driven by a Combined ratio around 81. These targets are based on the current level of interest rates, currency levels, and normalized levels of large and weather claims. The return on own funds is targeted between 35-40% in 2027, supported by a de-risking of the investment portfolio. During October and November 2024, Tryg sold DKK 7.4 bn of equities,...

Continue reading

VSMC Celebrates Breaking Ground on 300mm Fab in Singapore

Initial production slated for 2027, expected output of 55,000 300mm wafers per month in 2029VSMC Celebrates Breaking Ground on 300mm Fab in SingaporeThe event was attended by (from left to right): Yvonne Lim, Group Director, JTC; Mike Mevissen, Senior Vice President, NXP Semiconductors; Andy Micallef, Executive Vice President and Chief Operations and Manufacturing Officer, NXP Semiconductors; Dr. Tan See Leng, Minister for Manpower and Second Minister for Trade and Industry; Leuh Fang, Chairman, VSMC and VIS; F.C. Tseng, Vice Chairman, VIS; Arthur Chuang, Vice President, TSMC; Cindy Koh, Executive Vice President, EDBSINGAPORE, Dec. 04, 2024 (GLOBE NEWSWIRE) — VisionPower Semiconductor Manufacturing Company Pte Ltd (VSMC), the joint venture formed in September, 2024 by Vanguard International Semiconductor Corporation (VIS,...

Continue reading

Squalene Market to Witness 6.80% CAGR by 2031 | SkyQuest Technology

The various advantages of the squalene market include its uses in health and Wellness, cosmetics and personal care, pharmaceutical, and industrial applications. Westford, USA, Dec. 04, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that squalene market size will attain the value of USD 276.08 Million by 2031, with a CAGR of 6.80% during the forecast period (2024-2031). Squalene helps to boost, enhance and strengthen the immune system, enhance the immune system. Squalene has gained attention in the food industry as a functional ingredient due to its potential health benefits. It has immunomodulatory and anti-inflammatory properties, making it a valuable ingredient in the manufacture of functional foods and nutrients. The demand for functional foods and nutrients has helped the squalene market to grow in the industry. Overall, squalene’s...

Continue reading

Newborn Screening Market to Witness 6.8% CAGR by 2031 | SkyQuest Technology

The emergence of congenital disorders among newborns is projected to drive the growth rate in the newborn screening market. Westford, USA, Dec. 04, 2024 (GLOBE NEWSWIRE) — SkyQuest projects that Newborn Screening Market size will attain the value of USD 2.12 Billion by 2031, with a CAGR of 6.8% during the forecast period (2024-2031). The rising neonatal population, increasing cases of congenital diseases in newborns and growing consumer awareness are factors estimated to propel newborn screening industry growth over the forecast period. In addition, technological advancements in screening methodologies are also expected to boost the market. These kinds of congenital anomalies consist of genetic disorders, hearing impairment, and metabolic issues. It is crucially important to diagnose such anomalies early because a proper intervention...

Continue reading

Burning Rock Reports Third Quarter 2024 Financial Results

GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2024. Recent Business UpdatesTherapy SelectionPresented study results at the 2024 World Conference on Lung Cancer in September 2024. “Neoadjuvant sintilimab plus chemotherapy could be an optional treatment modality in selected EGFR-mutant NSCLC” and “Distinct Genomic and Immune Microenvironment Features of Solid or Micropapillary Predominant Subtype in Stage I Lung Adenocarcinomas”. Signed a strategic cooperation agreement with MGI Tech Co., Ltd in October 2024, aiming to fully complement each other’s...

Continue reading

Group Covenant Logistics Group Celebrates Dual Recognition for Safety Excellence

Company honored as Rand McNally Safety Program of the Year, while Marshall Rushworth receives Safety Leader of the Year award for transformative leadership in fleet safety CHATTANOOGA, Tenn., Dec. 04, 2024 (GLOBE NEWSWIRE) — Covenant Logistics Group, Inc. (NYSE: CVLG), a leading transportation and logistics provider, is proud to announce its recognition as a Rand McNally Safety Program of the Year winner for 2024. This recognition celebrates Covenant’s dedication to advancing fleet safety through proactive management, innovative technology, and a deeply ingrained safety culture. In addition to this prestigious honor, Covenant’s Marshall Rushworth, Director of Fleet Safety Technology, was named the Rand McNally 2024 Safety Leader of the Year. This individual award highlights Rushworth’s visionary leadership in building and guiding...

Continue reading

Intuitive Machines Prices Upsized $110.0 Million Offering of Shares of its Class A Common Stock and Concurrent Private Placement

HOUSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) — Intuitive Machines, Inc. (Nasdaq: LUNR, LUNRW) (“Intuitive Machines” or the “Company”), a leading space exploration, infrastructure, and services company, announced today the pricing of an upsized offering of 9,523,810 shares of its Class A common stock (“Class A Common Stock”) at a price to the public of $10.50 per share (the “Public Offering Price”) (the “Offering”). As part of the Offering, the Company and a selling stockholder granted the underwriters a 30-day option to purchase up to an additional 1,275,714 and 152,857 shares of Class A Common Stock from the Company and such selling stockholder, respectively. The Offering is expected to close on December 5, 2024, subject to customary closing conditions. Additionally, the Company will issue 952,381 shares of Class A Common Stock to...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.